Fludarabine, thiotepa and total body irradiation (TBI) has been used as conditioning in haplo-identical transplantation. We studied this conditioning regimen in adults undergoing matched sibling transplantation and alternative donor transplantation. A total of 30 consecutive patients underwent matched related, haplo-identical related or matched unrelated donor transplantation with fludarabine, thiotepa and TBI conditioning. All but four had advanced hematologic malignancies. For haploidentical transplant, ATG was added to the regimen. All patients received peripheral blood stem cells; these were Tcell depleted for 2-antigen or 3-antigen mismatched related transplantation. Additional graft-versus-host disease prophylaxis consisted of tacrolimus and minimethotrexate. One recipient of haplo-identical transplant failed to engraft; all other evaluable patients had prompt engraftment. Four patients died of regimen-related toxicity. In all, 14 additional patients died of regimenrelated causes including four from failure to thrive with persistent thrombocytopenia and four from delayed pulmonary toxicity. Six patients relapsed. Progressionfree survival at 12 months was 47% (90% CI: 25-69%) for recipients of HLA-identical sibling transplants and 30% (90% CI: 14-46%) for all patients. Five of six longterm survivors have extensive chronic GVHD. As a result of the delayed complications and a relatively high recurrence rate, we abandoned this regimen. Bone Marrow Transplantation (2003) 32, 9-13. doi:10.1038/ sj.bmt.1704088 Keywords: transplantation; TBI; fludarabine; thiotepa; toxicity Allogeneic transplantation is curative for only a limited proportion of patients with advanced hematologic malignancies. Its impact is limited because of high recurrence rates and because of treatment-related complications in patients with considerable comorbidities. We studied a conditioning regimen containing fludarabine, thiotepa and total body irradiation (TBI). A similar regimen had previously been used in recipients of haplo-identical transplants.
toxicity
Allogeneic transplantation is curative for only a limited proportion of patients with advanced hematologic malignancies. Its impact is limited because of high recurrence rates and because of treatment-related complications in patients with considerable comorbidities. We studied a conditioning regimen containing fludarabine, thiotepa and total body irradiation (TBI). A similar regimen had previously been used in recipients of haplo-identical transplants. 1 Based on its reported favorable toxicity profile and its excellent antileukemic and immunosuppressive properties, we expanded its use to recipients of HLAidentical transplants and matched unrelated donor transplantation. We report safety data of 30 consecutive patients treated with this regimen.
Patients and methods

Patients and protocol design
Patients were eligible if they had hematologic malignancies including acute and chronic leukemia and myeloproliferative disorders, non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma. Patients with acute leukemia in first remission were enrolled only if they had adverse prognostic characteristics at diagnosis.
Eligibility criteria included, Karnofsky performance status greater than or equal to 60%, bilirubin less than or equal to 2 mg/dl, creatinine less than 1.5 times normal.
The trial was designed as a single-arm phase II equivalence trial using methodology developed by Thall et al. 2 The four elementary patient outcomes, each defined over the period of 180 days post-transplant were death, relapse (alive and engrafted but relapsed prior to day 180), graft failure (alive and not engrafted at day 180, without relapse) and success (alive and engrafted without relapse at day 180). These four outcomes were defined to be mutually exclusive. Early stopping rules were formulated to close the trial if the death rate by day 180 exceeded 40%, the graft failure rate 10% or the relapse rate 25%. These outcomes were calculated based on historical data in patients with advanced hematologic malignancies. If none of the early stopping rules were exceeded, the protocol was to continue accrual until a total of 46 patients had been accrued.
The protocol was approved by the institutional review board of the University of Illinois at Chicago. All patients and donors provided written informed consent.
Fludarabine-thiotepa-TBI
Fludarabine 25 mg/m 2 /day was administered for five consecutive days (days À6, À5, À4, À3, À2). Thiotepa 5 mg/kg/day was administered on days -6 and -5. TBI 2 Gy b.i.d. was administered on days -3, À2 and -1 using previously reported methodology. 3 For five recipients of 2-antigen and 3-antigen mismatched related transplantation and for five recipients of matched unrelated donor transplantation, the dose of fludarabine was increased to 30 mg/m 2 /day. They also received antithymocyte globulin (ATGAM) 30 mg/kg/day i.v. on days -4, À3,À2 and -1.
Donor stem cell mobilization and stem cell processing
A total of 19 HLA-identical sibling donors, and one 1-antigen mismatched related donor underwent stem cell mobilization using G-CSF 5 mg/kg b.i.d. for five consecutive days. Collection was started on day 5 and continued daily until 5 Â 10 6 CD 34 cells/kg were collected. Five haplo-identical related donors received a G-CSF dose of 8 mg/kg subcutaneously every 12 h. In these five patients, leukapheresis was started on the fourth day of G-CSF administration, and continued until a target CD34+ cell dose of 15-20 Â 10 6 CD34+ cells/kg recipient weight had been collected. For haplo-identical recipients, donor cells were T-cell depleted using the Baxter Isolex 300i system or the Miltenyi Clinimax prior to cryopreservation. Five unrelated donors underwent one or two stem cell collections after G-CSF mobilization as per NMDP policy. Stem cells from unrelated donors were infused without further manipulations.
Graft-versus-host disease (GVHD) prophylaxis
All patients received GVHD prophylaxis consisting of tacrolimus and mini-methotrexate. Tacrolimus was given from day -2 until day 180. The dose was adjusted to achieve levels of 5-15 ng/ml. Thereafter, tacrolimus was tapered unless there was evidence of acute or chronic GVHD. Methotrexate 5 mg/m 2 was administered on days +1, +3 and +6 after transplantation. [4] [5] [6] Supportive care and growth factors Most patients received G-CSF 5 mg/kg/day subcutaneously starting on day 7 after transplantation until a neutrophil count of 41.5 Â 10 9 /l. for three consecutive days had been reached. Recipients of 2-antigen or 3-antigen mismatched related transplants received GM-CSF 250 mg/m 2 /day starting on day 7, based on data suggesting that G-CSF might affect immune recovery in this setting. 7 All patients received levofloxacin 500 mg/day PO until resolution of neutropenia, and fluconazole 200 mg/day until day 180. Trimethoprim/sulfamethoxazole 2 double strength tablets daily twice a week, was given from engraftment until 1 year after transplantation. Acyclovir 10 mg/kg i.v. q 8 h until discharge and thereafter 800 mg p.o. b.i.d. or t.i.d. until day 180 was administered to all patients except for those receiving ganciclovir, or those who were both HSV negative, and CMV negative and who had a CMV-negative donor.
Prophylactic ganciclovir was given as previously described to recipients of haplo-identical T-cell depleted transplantation. 8 All other patients were screened weekly for CMV-viremia and treated with ganciclovir upon detection of CMV-viremia. Antifungal, antiviral and PCP prophylaxis continued indefinitely for those with active GVHD or those on immunosuppressive treatment.
All patients were treated in high-efficiency, particulatefree air (HEPA) filtered rooms with strict reverse isolation. Irradiated and leukodepleted blood products were administered to maintain a hemoglobin level of greater than 8 g/dl and platelet count of greater than 20 Â 10 9 /l.
Post-transplant evaluation
Patients were scored as treatment failures when overt progression of disease by clinical, radiological or pathological criteria was documented, or when they died from transplant-related causes.
Regimen-related. toxicity was scored using the criteria of Bearman et al. 9 In this system, grade I toxicity is reversible without treatment, grade 2 is not life threatening, but requires treatment. Grade 3 requires life-support intervention, and grade 4 is fatal. Regimen-related toxicity in each organ system was scored as the highest grade achieved in that organ system through day 28, except that deaths occurring after day 28 as a result of regimen-related toxicity occurring before day 28 were also scored as Grade 4. Adverse events that could be attributed to infection (culture documented), bleeding or other medications were not scored as regimen-related toxicity. The maximum toxicity was the highest grade recorded in any individual organ system and the cumulative toxicity score was the sum of the highest grades recorded for all eight organ systems.
Patients were evaluated for acute and chronic GVHD, and GVHD was scored and treated according to standard criteria. 10 
Engraftment analysis
Bone marrow and/or peripheral blood specimens were collected at approximately days 28, 100 and 180 following transplant. Donor and recipient cells were detected by quantitative analysis of informative microsatellite sequences of DNA as previously described.
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Statistical methods
Progression-free survival and overall survival were calculated using the Kaplan-Meier product-limit estimate and expressed as probabilities with a 95% confidence interval (CI). 12 The long-term outcome analysis was performed for the entire patient group and separately for recipients of HLA-identical sibling transplantation.
Results
Patients
From 1997 until July 2001, 30 consecutive patients were enrolled. Their characteristics are summarized in Table 1 . Median age at transplantation was 41 (range 12-61). Except for three patients with CML in chronic phase and one patient with AML in first remission, all patients had advanced hematologic malignancies. In all, 17 patients had advanced stages of AML, MDS or CML. Nine patients had advanced lymphoma, myeloma, CLL or ALL. Two patients had undergone a prior autologous or allogeneic transplantation.
A total of 25 patients received unmanipulated peripheral blood progenitor cells (PBPC). Five recipients of 2 antigen or 3 antigen mismatched related donor transplants received T-cell-depleted PBPC.
Engraftment
One recipient of haplo-identical T-cell-depleted stem cells failed to engraft. Trilineage hematopoietic recovery occurred in all other evaluable patients. Chimerism studies demonstrated 100% donor chimerism in blood and bone marrow in all these patients by day 28.
Early regimen-related toxicity, treatment-related mortality and GVHD
Regimen-related toxicities are summarized in Table 2 and the causes of treatment failure in Table 3 . As shown in Table 3 , the incidence of regimen-related toxicity and delayed complications were similar after HLA-identical sibling transplantation and matched unrelated donor transplantation. The most common regimen-related toxicities were mucositis, pulmonary, hepatic and renal toxicity. Severe CNS, cardiac, bladder or GI-toxicity was not observed. Four of 30 patients died of regimen-related toxicity. All four were heavily pretreated patients who underwent transplantation for refractory disease. Three developed multiorgan failure and one died from pulmonary toxicity. Besides the four regimen-related deaths, 14 other patients died from treatment-related causes. The haploidentical recipient with graft failure died of multiorgan failure. Another recipient of a haplo-identical transplant died of a post-transplant lymphoproliferative disorder. One HLA-identical sibling transplant recipient died of sepsis and one of hemorrhage. Four patients had a syndrome of failure to thrive combined with profound thrombocytopenia. All of them had had acute GVHD, but in only one case was this syndrome associated with overt chronic GVHD. Three of them died between 4 and 5 months after transplantation and one died 18 months after transplantation from overwhelming sepsis.
Four patients died of delayed pulmonary complications. This included a haplo-identical and an unrelated donor transplant recipient, and both died at 2 months from idiopathic pneumonitis, attributed to radiation toxicity. Autopsy was performed in one case and showed diffuse alveolar damage. Two recipients of matched sibling transplant developed delayed pulmonary complications as well. A 21-year-old woman with a history of grade II acute skin GVHD developed bronchiolitis obliterans and died at 20 months post-transplant from respiratory failure and thrombotic thrombocytopenic purpura (TTP). A 53-yearold man with a history of grade III acute skin GVHD developed pulmonary veno-occlusive disease that responded partially to treatment with steroids. He died of a Fludarabine-thiotepa-TBI conditioning in allogeneic transplantation K van Besien et al fungal infection and idiopathic liver failure after prolonged treatment with liposomal amphotericin. Only one case of grade III acute GVHD was observed among the 19 recipients of HLA-identical sibling donor transplantation. None was observed among the recipients of T-cell-depleted haplo-identical transplantation. By contrast, two recipients of unrelated donor transplantation died of grade IV acute GVHD. Five of the six long-term survivors developed chronic GVHD, and four continue to require treatment.
Progression-free survival and survival and disease recurrence
Kaplan-Meier progression-free survival at 12 months was 47% (90% CI: 25-69%) for recipients of HLA-identical sibling transplants, and 30% (90% CI: 14-46%) for all patients (Figure 1 ). Relapse occurred in six patients, for a cumulative relapse rate of 32% (90% CI: 10-58%). Longterm survivors include two of three patients transplanted for CML in chronic phase, one patient with AML in first remission, one patient transplanted for refractory CLL with pancytopenia and one patient with large-cell lymphoma who had failed a prior autologous transplant. The median follow-up for survivors is 30 months (range 29-57 months).
Discussion
Failure rates after allogeneic transplantation for advanced hematologic malignancies remain high. 13, 14 Treatmentrelated mortality and disease recurrence constitute closely inter-related causes of treatment failure. Efforts to decrease disease recurrence by dose-intensifying chemotherapy or radiation, 15 or by induction of GVHD, 16 have been largely unsuccessful because of increased complication rates.
In this study, we evaluated the efficacy of the combination of TBI, thiotepa and fludarabine. This conditioning regimen is modeled after the one used by Aversa et al 1 for conditioning in haplo-identical transplantation. We extended its use to matched sibling transplantation based on the activity of thiotepa in hematologic malignancies, 17 and the known synergy between fludarabine and radiation which potentially might increase efficacy without affecting regimen-related mortality. 18, 19 It was hypothesized that the combination would have acceptable toxicity because of the limited extramedullary toxicities of fludarabine at doses used in this study. We used G-CSF mobilized peripheral blood as a source of stem cells because they are associated with improved outcome in patients with hematologic malignancies. 13, 14 For patients undergoing alternative donor transplantation, ATG was added to the conditioning regimen and the dose of fludarabine was slightly increased. Engraftment occurred in 29 of 30 recipients including in four of five cases of T-cell-depleted haplo-identical transplants, and in all cases of unrelated donor transplants. The only case of graft rejection occurred after TBI-based conditioning in a haplo-identical transplant recipient.
Mucosal, pulmonary, renal and hepatic toxicity were the main toxicities and were the primary cause of death for three patients. Given the advanced status of the underlying malignancy and the extensive previous treatment many of our patients had undergone, this is an acceptable result.
Unfortunately, delayed toxicity was considerable. Four patients died from a syndrome of failure to thrive combined with prolonged pancytopenia. Three of the four patients had had acute GVHD and one had overt chronic GVHD. It is possible that this syndrome was an expression of chronic GVHD. 20 Four patients died from delayed pulmonary complications, one each from idiopathic interstitial pneumonia, diffuse alveolar damage, bronchiolitis obliterans and pulmonary veno-occlusive disease. By contrast, Aversa et al, 1 did not report delayed pulmonary complications after conditioning with fludarabine, thiotepa and TBI. The etiology of noninfectious pulmonary complications is multifactorial, and affected by the conditioning regimen as well as by the severity of chronic GVHD. 21, 22 Thus, we speculate that differences in patient population, TBI technique and GVHD prophylaxis between our patients and those reported from Italy played a role in the observed differences in delayed pulmonary toxicity between the two series. Aversa et al 1 studied a patient population with a median age of 22, and TBI was administered in a single-dose fraction. They also used profound T-cell depletion as the main form of GVHD prophylaxis with a resulting low incidence of either acute or chronic GVHD. We treated older adults and used unmodified peripheral blood stem cells in the majority of patients. This was associated with a high incidence of extensive chronic GVHD, 23 likely contributing to the occurrence of severe delayed pulmonary side effects.
In summary, the fludarabine-thiotepa-TBI regimen as used in the current study was associated with an acceptable rate of regimen-related toxicity, but a rather high incidence of delayed complications. As a result of a relatively high rate of disease recurrence in patients with advanced hematologic malignancies, we concluded that this regimen did not offer substantial promise and that further accrual to the initially planned 46 patients was not warranted. Figure 1 Disease-free survival.
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